MEDICA and EBCC
Cerca Biotech was well represented last week at both MEDICA 2022 and the EBCC13 meeting in Barcelona. A step forward in the world of breast cancer care This was a great week for Cerca Biotech, and now we’re back into the busy world of oncology at its best! We finished the week energised and ready to keep working to make sure that breast cancer diagnostics can be revolutionised using modern technology.
New multigene breast cancer test could speed up accurate diagnosis for women, evidence suggests
Every breast cancer tumour is unique. Accurate subtyping of breast cancer tumors is essential to determine the type of treatment that the disease is likely to respond to. This has become especially important in hard to diagnose triple negative and HER2-low cases where new immunotherapy drugs have been recently approved for use.
November is a busy month for the team at Cerca Biotech
At EBCC we’re presenting exciting new research, as part of the ‘optimal diagnosis’ sessions. The data compares MammaTyper® to traditional immunohistochemistry (IHC) from three different reference centre cohorts in needle core biopsies of breast cancer
Treatment for triple-negative breast cancer will now be available for patients in England
The rapid diagnosis, subtyping and identification of tumours, including those that are triple-negative, is key to the fight against breast cancer.
World Evidence-Based Healthcare Day
Why the research and the people behind MammaTyper® matter.
Low HER2 breast cancer: progress in treatment needs progress in diagnostics.
Improving accurate detection of low HER-2 breast cancers.
Cerca Biotech
Cerca Biotech is the European subsidiary of Shuwen Biotech, who you might already recognise as being a highly reputable and innovative molecular and point of care diagnostics organisation.
MammaTyper® is a new tool for subtyping breast cancer.
READ MORE +
A rapid, simple, Point Of Care screening test for urinary congophilia.
READ MORE +ABOUT US
Cerca Biotech
Cerca Biotech is the European subsidiary of Shuwen Biotech, a highly reputable and innovative molecular and point of care diagnostics organisation. Shuwen and Cerca are passionate about healthcare and are working to create world-leading innovations in the fields of Oncology and Women’s Health.
High-performance test
Quantitative RT-qPCR assay (CE marked IVD)
- Highly reproducible biomarker assessment
- Reliable results through standardized biomarker detection
- Accurate stratification of breast cancer tumors into St Gallen subtypes
Promising clinical utility
Clinical value validated in numerous performance evaluation studies
- Outperforms IHC by accurate Ki-67 determination
- Provides information on patient‘s prognosis
- Accurate subtyping supports treatment decisions
Easy-to-use
Clinical value validated in numerous performance evaluation studies
- Reliable method for any molecular pathology laboratory
- Validated for multiple qPCR instruments*
- From resection or core needle biopsy FFPE sample to result within 6 hours FFPE = formalin fixed paraffin embedded
NEWS
Recent article and news
MEDICA and EBCC: Rich’s Conference Diary
Cerca Biotech was well represented last week at both MEDICA 2022 and the EBCC13 meeting in Barcelona. Interest in MammaTyper® at MEDICA; the interest was for both our MammaTyper® RT-PCR breast cancer subtyping assay and the newly released CercaTest Pre-eclampsia Vue™ point of care test. Breast cancer innovation showcased at EBCC The 13th European Breast Cancer Conference (EBCC) in Barcelona saw clinicians involved in breast cancer care from across Europe and beyond descend on Barcelona for a three-day meeting.
New multigene breast cancer test could speed up accurate diagnosis for women, evidence suggests
Three new research studies have concluded that MammaTyper could provide a reliable, efficient, and reproducible alternative to the molecular subtyping of breast cancer tumours.
Research Project N.1 from Univ. Birmingham (UK)
Breast cancer biomarkers help clinicians determine a patient’s breast cancer sub-type. This plays a vital role in tailoring treatment effectively. Newer multigene tests such as MammaTyper® go further in assessing intrinsic properties of breast cancer tumours that impact on tumour behaviour.